ANRS CO3 Aquitaine/AQUIVIH-NA Cohort
The ANRS CO3 Aquitaine/AQUIVIH-NA cohort aims to study the natural history and treatment of HIV-1 infection in Aquitaine.
Last updated on 22 September 2025
In brief
Coordinating investigator
Pr Fabrice Bonnet
Sites/Teams
Department of Internal Medicine and Infectious Diseases, Hôpital Saint-André, Bordeaux University Hospital
COREVIH (Denis Lacoste, Sylvie Lawson-Ayayi, Isabelle Pellegrin, Hervé Fleury, Dominique Breilh, Stéphane Bouchet, Patrick Blanco)
Methodology and Management Unit CMG-EC Inserm U1219/ANRS (Linda Wittkop)
Status
on going
Pathology
HIV
Funding
ANRS MIE
Bordeaux University Hospital
Comorbidities and antiretroviral evaluation in people living with HIV
The survival rate of people living with HIV (PLHIV) treated with antiretroviral drugs (ARVs) is now close to that of the general population. Nevertheless, people living with HIV suffer from an excess of comorbidities (which the ANRS CO3 Aquitaine/AQUIVIH-NA cohort helped to describe).
The following factors explain this excessive comorbidity and may also constitute possible avenues for intervention::
- immunosuppression
- immune activation
- exposure to numerous cardiovascular and cancer risk factors
- ageing.
What is the ANRS CO3 Aquitaine/AQUIVIH-NA cohort?
- This is an open, multicentre, prospective epidemiological cohort study with a biobank, which began collecting hospital data on HIV infection in 1987. Established by the Aquitaine Clinical AIDS Epidemiology Group (GECSA), it subsequently established partnerships with the national HIV infection surveillance systems of the Ministry of Health (since 1991) and through its ANRS certification in 1992.
- This cohort is funded by Bordeaux University Hospital and ANRS MIE.
What is the objective of the ANRS CO3 Aquitaine/AQUIVIH-NA cohort?
Long-term monitoring is necessary to detect and understand the evolution of morbidities, the emergence of HIV complications, immunodepression and immuno-inflammation/immuno-senescence, as well as the side effects of the most recently marketed ARVs. Furthermore, comprehensive health assessment involving not only medical determinants but also psychological and social determinants, will be one of the public health challenges over the next decade in the field of HIV infection – as in other chronic diseases.
Main objective
The objective of the ANRS CO3 Aquitaine/AQUIVIH-NA cohort is to study the natural history and treatment of HIV-1 infection in Aquitaine.
Secondary objectives
- Identify the determinants of infection progression (death, AIDS events, comorbidities and event-free survival, etc.)
- Determine/identify the prognostic factors of this progression
- Evaluate the modalities of care for PLHIV and study their impact on the disease progression
- Carry out hospital epidemiological surveillance of HIV infection in the Aquitaine region
- Identify emerging medical and psychosocial issues among PLHIV followed in the healthcare system
- Analyse all healthcare utilization by PLHIV since 2013
- Analyse the determinants of health service utilization and inequalities in care according to patient profiles (clinical-biological, quality of life, etc.)
Report on indicators of care for people living with HIV in COREVIHs in France for the year 2023
Data from the ANRS CO3-AQUIVIH-NA cohort, together with data from the ANRS-CO4 FHDH cohort, contribute to prepare the report on indicators of care for PLHIV over the age of 18 in COREVIHs in France. The 2023 report presents a detailed analysis of data between 2019 and 2023. It includes:
- The number and characteristics of new patients receiving care
- The proportion of patients receiving care at an advanced stage
- Changes in the number of active cases monitored
- Indicators of antiretroviral treatment and virological response
- Regional data by COREVIH and for the Île-de-France region
Examples of research projects involving the ANRS CO3 Aquitaine/AQUIVIH-NA cohort
The QUALICOV project
This project involves questionnaires that suplement the sub-study on health-related quality of life (‘QualiV’) within the ANRS CO3/AQUIVIH-NA cohort. The aim is to study the impact of the health crisis on the continuity of care and physical health, living conditions and mental health of people living with HIV.
The QUALIV project
This project is a sub-study of the ANRS CO3 /AQUIVIH-NA cohort. Its objective is to study changes in health-related quality of life and what affects it.
The COG-LOC 2 project
This project was conducted to identify the factors associated with poore cognitive and locomotor performance at 10 years in people living with HIV who participated in the COG-LOC study between 2007 and 2009.
Publications
- Chaussade H, et al. Incidence of lung and human papilloma virus-associated malignancies in HIV-infected patients. AIDS. 2022 Apr 1;36(5):665-673. DOI: 10.1097/QAD.0000000000003152. PMID: 34923517. https://pubmed.ncbi.nlm.nih.gov/34923517/.
- Hémar V, et al. A comprehensive analysis of excess depressive disorder in women and men living with HIV in France compared to the general population. Sci Rep. 2022 Apr 16;12(1):6364. DOI: 10.1038/s41598-022-10263-3. PMID: 35430622; PMCID: PMC9013369. https://pubmed.ncbi.nlm.nih.gov/35430622/
- Nyamankolly E, et al. Long-term follow-up of HIV-1 multidrug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: toward drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018. Int J Antimicrob Agents. 2022 Dec 2:106696. DOI: 10.1016/j.ijantimicag.2022.106696. Epub ahead of print. PMID: 36470511. https://pubmed.ncbi.nlm.nih.gov/36470511/
- Trickey A, et al. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. The Lancet HIV, Volume 9, Issue 6, 2022, Pages e404-e413, ISSN 2352-3018, https://doi.org/10.1016/S2352-3018(22)00046-7. https://pubmed.ncbi.nlm.nih.gov/35659335/
Our selection
Generic call for proposal HIV/AIDS, STIs, viral hepatitis, tuberculosis (2026-1)
Opening dates: 16 June – 15 September
16 June 2025
40 years after the discovery of HIV: research nurtures the hope of remission
Nearly 39 million people worldwide are carriers of the human immunodeficiency virus (HIV), and a further 1.3 million people contracted HIV in 2022. Forty years after the discovery of the virus at the Institut Pasteur, HIV research is still active, with the aim of better understanding the mechanisms…
01 December 2023
